Mechanism behind gut bacteria anti-inflammatory effect revealed

By Nikki Hancocks contact

- Last updated on GMT

Getty | Claudio Ventrella
Getty | Claudio Ventrella

Related tags: Anti-inflammatory, Bifidobacterium, COVID-19

A surface protein of the intestinal bacteria Bifidobacterium is capable of stopping excessive or uncontrollable inflammation caused by viruses such as COVID-19, according to a newly published study.

Bifidobacteria are the prevalent group of bacteria inhabiting the gastrointestinal tract (GIT) of healthy children and amounting to a few percent of the total gut microbiota in adults. They are known to play a significant role in shaping and sustaining the immune system. Today there is mounting evidence emphasising the immunomodulatory properties of bifidobacteria, which are due to both their cell components​ and metabolites​.

When in danger, the cells of our body send out an SOS signal that is received by other cells and causes an immune response. This is how inflammation starts. This call to action is transmitted by special peptides known as anti-inflammatory cytokines. Sometimes there are too many of them, and a so-called cytokine storm occurs. This dangerous and sometimes deadly reaction is observed in severe cases of COVID-19. 

However, some pathogenic bacteria know how to trick our body's protective systems: they use special proteins to capture cytokines and reduce inflammation. Until recently scientists had been unaware whether bifidobacteria have the same effect on the inflammatory process. 

In the current study, published in Anaerobe​ journal, a team of researchers from Moscow studied how FN3, a surface protein of Bifidobacterium longum, blocks or binds cytokines. FN3 helps cells attach to different surfaces, including intestinal walls covered in mucus. Moreover, it has two protein-carbohydrate moieties (fibronectin domains) that are similar to human cytokine receptors. The experiment showed that FN3 is able to bind TNF-α, one of the main cytokine storm factors.

To find out what specific cytokines are bound by FN3, the team used a method called ELISA (Enzyme-Linked ImmunoSorbent Assay) and applied it to a protein fragment with a fibronectin domain. First, antibodies that react only with FN3 were secured on a base. Then, a fragment of FN3, cytokines, and antibodies to them bound with a fluorescent tag were added. As a result, the team built a sandwich-like structure: antibody-FN3-cytokine-antibody.

Of four cytokines that belonged to different classes, only the tumor necrosis factor TNF-α showed effective binding. The fact that bifidobacterial surface proteins were able to recognise specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.

Studies like this are especially important for understanding the processes of immune development in newborn babies, as their intestinal microbiome almost entirely consists of bifidobacteria. Biologists also believe that the tumour necrosis factor-specific fragment of FN3 can reduce the levels of cytokine storm in COVID-19 patients.

"Studies of cytokine-binding properties of microorganisms have become extremely important recently in view of the current epidemiological situation. Uncontrollable inflammation or cytokine storm is one of the most prominent elements of COVID-19 pathogenesis," ​said Prof. Valery Danilenko, a PhD in Biology from RUDN University, in Moscow. 

"Selective binding of TNF-α, one of the key factors of inflammation, with a fragment of the FN3 protein of Bifidobacterium longum opens a prospect for developing new medicinal drugs that would slow down the cytokine reaction. It has already been agreed that a preclinical trial of a new FN3-based anti-inflammatory medication should be conducted as quickly as possible."

Source: Anaerobe

Dyakov. I. N., et al

"FN3 protein fragment containing two type III fibronectin domains from B. longum GT15 binds to human tumor necrosis factor alpha in vitro"

 https://doi.org/10.1016/j.anaerobe.2020.102247

Related topics: Research

Related news

Show more

Sportsandactivenutrition

SERIES INTRODUCTION

23 SEPTEMBER 2020 | 10.30AM CET


Follow us

Products

View more

Webinars